1. Abbvie is Buying Botox-Maker Allergan in a $63 Billion Pharma Mega-Deal

    Abbvie is Buying Botox-Maker Allergan in a $63 Billion Pharma Mega-Deal
    • AbbVie has agreed to buy Allergan in a $63 billion cash-and-stock deal.
    • Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share that they hold, totaling $188.24 per Allergan share.
    • The offer represents a 45% premium to the closing price of Allergan's shares on Wednesday...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone.
  3. Topics Mentioned

  4. Authors